BLFS at a glance
BIOLIFE SOLUTIONS INC (BLFS, SEC CIK 834365) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on October 6, 2026 and Form 4 insider filings as recently as September 22, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), BIOLIFE SOLUTIONS INC (BLFS) reported revenue of $96.2 million (up 17.0% from FY2024) and a net loss of $4.6 million. Diluted EPS was -$0.10.
- As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding BIOLIFE SOLUTIONS INC (BLFS) shares worth $561.4 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $96.2M
- +17.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 28 funds
- $561.4M · +2 vs prior quarter
- Latest 8-K
- Sep 9, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $28.5M, up $5.0M or 21% YoY, driven by biopreservation media demand
- Gross margin 64% vs 65% YoY, reflecting less favorable product mix and higher lower-margin sales
- Best-performing offering biopreservation media, with demand driving quarterly revenue growth
- Cash, equivalents and securities $113.1M vs $120.2M at December 31, 2025
- Six-month operating cash flow $5.9M vs $9.1M; $11.5M financing outflow included $6.7M tax-withholding payments
Risk Factors
- Risk factors section not provided; supplied text contains Items 2–6 and signatures only
- Merger agreement dated July 21, 2026, with Repligen Corporation and merger subsidiaries disclosed as an exhibit
AI summary of the BLFS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- HSR antitrust waiting period expired September 3, clearing a key regulatory condition for Repligen’s acquisition of BioLife
- Consideration remains $11.25 cash plus 0.1442 Repligen shares per BioLife share
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 unaudited financial results and operational highlights announced for quarter ended June 30, 2026
- Results furnished in Exhibit 99.1, requiring review for revenue, profitability, guidance, and operational trends
AI summaries of BLFS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BLFS
Don't miss the next BLFS filing
- Alerts as it files. A push when BLFS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BLFS, by share count.
- Ask anything. An AI agent that reads every BLFS filing and answers with sources.
BLFS alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Werner Sean | F | Sep 18, 2026 | 421 | $36.69 |
| Wichterman Troy | F | Sep 18, 2026 | 937 | $36.69 |
| DE GREEF RODERICK | F | Sep 18, 2026 | 2,775 | $36.69 |
| Berard Todd | F | Sep 18, 2026 | 470 | $36.69 |
| Mathew Aby J. | F | Sep 18, 2026 | 564 | $36.69 |
| Berard Todd | F | Sep 8, 2026 | 356 | $35.38 |
| Mathew Aby J. | F | Sep 8, 2026 | 627 | $35.38 |
| Wichterman Troy | F | Sep 8, 2026 | 1,026 | $35.38 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $82.3M | $96.2M |
| Gross Profit | $41.3M | $50.1M | $62.1M |
| Operating Income | - | -$7.1M | -$16.6M |
| Net Income | - | -$20.2M | -$4.6M |
| Gross Margin | - | 60.9% | 64.6% |
| Op. Margin | - | -8.7% | -17.3% |
| Net Margin | - | -24.5% | -4.8% |
| Balance Sheet | |||
| Total Assets | - | $399.5M | $405.9M |
| Equity | - | $348.9M | $371.9M |
| ROE | - | -5.8% | -1.2% |
| Per Share | |||
| EPS | $-1.52 | $-0.44 | $-0.10 |
| Cash Flow | |||
| Operating CF | - | $8.4M | $20.1M |
| CapEx | - | $3.2M | $9.5M |
Source: XBRL data in BIOLIFE SOLUTIONS INC (BLFS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate BLFS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 28 | $561.4M |
| Q1 2026 | 26 | $383.8M |
| Q4 2025 | 25 | $518.5M |
| Q3 2025 | 27 | $522.3M |
| Q2 2025 | 27 | $424.2M |
| Q1 2025 | 23 | $318.5M |
| Q4 2024 | 19 | $326.9M |
| Q3 2024 | 16 | $209.7M |
- BlackRock+273.8K (+4%)
- Goldman Sachs Group+266.1K (+100%)
- State Street Corp+78.9K (+5%)
- Vanguard Portfolio Management LLC+48.2K (+6%)
- Vanguard Capital Management LLC+46.4K (+2%)
- Ameriprise Financial−834.3K (-93%)
- FMR LLC (Fidelity)−477.1K (-32%)
- Invesco Ltd−108.1K (-5%)
- D.E. Shaw & Co−89.5K (-88%)
- Citadel Advisors LLC−86.2K (-35%)
- Millennium Management+625.7K
- Allstate+19.4K
- AQR Capital Management+15.7K
- Renaissance Technologies LLC−207.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 191 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BLFS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 6, 2026 | - | - | - |
| SC 13G | Sep 24, 2026 | - | - | |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 8-K | Sep 9, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Jul 22, 2026 | - | Analysis | - |
| 4 | Jul 21, 2026 | - | - | - |
| 4 | Jul 13, 2026 | - | - | - |
| 4 | Jul 13, 2026 | - | - | - |
| 4 | Jul 13, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 10, 2026 | - | - |
Related Health Care companies
- AXGN · Axogen, Inc.Electromedical & Electrotherapeutic Apparatus
- CV · CapsoVision, IncElectromedical & Electrotherapeutic Apparatus
- CBLL · Ceribell, Inc.Electromedical & Electrotherapeutic Apparatus
- CNMD · CONMED CorpElectromedical & Electrotherapeutic Apparatus
- ELMD · Electromed, Inc.Electromedical & Electrotherapeutic Apparatus
- HYPR · Hyperfine IncElectromedical & Electrotherapeutic Apparatus
- ITGR · Integer Holdings CorpElectromedical & Electrotherapeutic Apparatus
- LIVN · LivaNova PLCElectromedical & Electrotherapeutic Apparatus
BLFS SEC filings: frequently asked questions
Which institutions hold BLFS stock?
As of June 30, 2026, the largest BIOLIFE SOLUTIONS INC (BLFS) holders among the 13F filers tracked by SignalX were BlackRock ($180.0 million), Invesco Ltd ($63.3 million), Vanguard Capital Management LLC ($55.5 million), State Street Corp ($46.8 million), Dimensional Fund Advisors ($29.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BLFS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), BIOLIFE SOLUTIONS INC (BLFS) reported revenue of $96.2 million (up 17.0% from FY2024) and a net loss of $4.6 million. Diluted EPS was -$0.10. The figures come from the XBRL data in the 10-K.
What did BLFS report in its latest 8-K?
BIOLIFE SOLUTIONS INC (BLFS) filed an 8-K on September 9, 2026 reporting Item 8.01 (Other Events). HSR antitrust waiting period expired September 3, clearing a key regulatory condition for Repligen’s acquisition of BioLife.
What are the latest BLFS SEC filings?
BIOLIFE SOLUTIONS INC (BLFS) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on October 6, 2026 and a Form 4 insider filing on September 22, 2026.
What is BLFS's SEC CIK number?
BIOLIFE SOLUTIONS INC (BLFS)'s SEC Central Index Key (CIK) is 834365. EDGAR lists every BLFS filing under that number.
Ask anything about BLFS
The research agent reads BLFS's filings, financials, insider trades and 13F holders, then answers with sources.